Ash 2022 – fast production fails to cure Car-T's problem

Novartis and Gracell’s two-day manufactured Cars do not solve cell therapy’s biggest bottleneck – yet.

Novartis stays the course on cell therapy bet after phase 1 data

63 'Buy It for Life' Products: Cast-Iron, Tools, Speakers, Chairs

Time to CAR T-cell Therapy May Impact Outcomes for Patients With

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell

Florida's Electric Vehicle Future - Tampa Hillsborough Expressway

Top Myeloma Research Presented at ASH 2022

ASH 2022: CAR T-Cell Therapy

Impact of COVID-19 Case Numbers on the Emission of Pollutants from

IMWG Conference Series: Reporting from ASH 2022

Tecvayli Information for Patients